Icelandic biotechnology company Alvotech has secured a €100 million senior term loan facility to strengthen its liquidity position and support continued investment in research, development, and global expansion through 2026. The financing underlines investor confidence in the company’s biosimilar strategy and long term growth plans.
Overview of the €100 million financing
The new term loan facility has been led by GoldenTree Asset Management and replaces Alvotech’s previously disclosed working capital facility. Under the agreement, Alvotech gains access to the full €100 million for the duration of the two year term, giving the company greater operational flexibility as it advances its product pipeline.
Key terms of the financing include:
- Loan size of €100 million
- Senior term loan structure
- Interest rate of 12.50 percent, payable monthly in cash
- Maturity of two years
- Full drawdown available throughout the loan term
According to Alvotech, the revised structure improves liquidity planning and allows the company to focus on execution rather than short term capital constraints.
Leadership perspective and strategic intent
Robert Wessman, Chairman and Chief Executive Officer of Alvotech, described the financing as a strong endorsement of the company’s long term vision.
He said the €100 million facility reflects GoldenTree’s continued alignment with Alvotech’s strategy and strengthens the company’s ability to invest in R&D, scale manufacturing, and deliver high quality biosimilar medicines to patients worldwide.
Wessman founded Alvotech in 2013 with the ambition of building a global leader focused exclusively on biosimilars. Since then, the company has invested heavily in in house development, manufacturing capabilities, and global commercial partnerships.
Also Read: Kraken: AI Powered Platform Transforming Global Utilities
What Alvotech does and why biosimilars matter
Alvotech specialises in the development and manufacture of biosimilar medicines. A biosimilar is a biologic medicine that is highly similar to an existing approved biologic, with no clinically meaningful differences in safety, purity, or potency.
Unlike traditional small molecule drugs, biologics and biosimilars are produced in living systems, which makes their development and manufacturing significantly more complex. However, biosimilars play a critical role in expanding patient access to life saving treatments by increasing competition and reducing healthcare costs.
Approved products and marketed biosimilars
Alvotech has already achieved significant commercial progress, with five biosimilars approved and marketed across multiple global markets.
These include biosimilars to:
- Humira (adalimumab)
- Stelara (ustekinumab)
- Simponi (golimumab)
- Eylea (aflibercept)
- Prolia and Xgeva (denosumab)
These medicines address large and established therapeutic markets, particularly in autoimmune diseases, ophthalmology, and bone health.
Development pipeline and future launches
Beyond its approved products, Alvotech has built a broad and advanced development pipeline.
Key pipeline highlights include:
- Nine disclosed biosimilar candidates currently in active development
- Target indications covering autoimmune disorders, eye diseases, osteoporosis, respiratory conditions, and cancer
- A total of around 30 products in development across various stages
The company plans four global product launches through 2026 and is expanding its production capacity and supply chain to support these milestones.
Recent financing activity and capital structure
The €100 million term loan adds to a series of recent financing initiatives that have strengthened Alvotech’s balance sheet.
Recent funding activity includes:
- €91.9 million senior unsecured convertible bonds placed in December 2025, due in 2030
- Repricing of an existing facility in June 2025 to an interest rate of SOFR plus 6.0 percent
- Strategic refinancing transaction arranged in June 2024, maturing in June 2029
All of these transactions were also led by GoldenTree Asset Management, highlighting a long standing financing relationship.
Global manufacturing and commercial partnerships
Alvotech is positioning itself as a global biosimilar platform rather than a regional player.
The company has established commercial partnerships to support market access across:
- The United States
- Europe
- Japan
- China
- Other Asian markets
- Parts of South America, Africa, and the Middle East
In parallel, Alvotech continues to invest in manufacturing scale and supply chain resilience to ensure reliable global supply as additional products reach the market.
Outlook for 2026 and beyond
With fresh capital in place, Alvotech is focused on executing its near term priorities. These include advancing its R&D pipeline, delivering multiple global launches, and strengthening its position in the fast growing biosimilars market.
As healthcare systems worldwide look to manage rising costs while expanding patient access to biologic therapies, companies like Alvotech are expected to play an increasingly important role in the global pharmaceutical landscape.